



Submission Instructions

Submissions must be provided by 5pm on FRIDAY 9 NOVEMBER 2018

The Jurisdictional Blood Committee (JBC) Working Group overseeing the update of the Patient Blood Management (PBM) Guidelines invites you to review and comment on the proposed research questions for the review of the evidence base for the update of the PBM Guidelines: Module 2 (Perioperative), Module 3 (Medical), Module 4 (Critical Care), Module 5 (Obstetrics and maternity) and Module 6 (Neonatal and paediatrics).

While the Working Group specifically seeks your input on the proposed research questions and associated PICO criteria (p13-31 of the research protocol), the entire research protocol has been provided to provide background information and context.

Your contribution is greatly appreciated.

How do I make a submission?

Please use the submission template to provide your feedback.

You will receive an acknowledgement via email when your submission has been received.

The NBA is unable to accept:

- Comments after the consultation deadline (**5pm on Friday 9 November 2018**)
- Comments which do not comply with these submission instructions
- Confidential information or other material that you would not wish to be made public
- Comments, which in the opinion of the NBA are inappropriate.

What contact details are required?

A 'cover sheet' is provided at p3 for your contact details as well as the contact details for the clinical college/society you are representing.

We might contact you during the consultation process to clarify or seek further information on any issues raised in your submission.

All submissions must be signed, and forwarded to the NBA by email, mail or facsimile.

How should I format my submission?

The submission template is provided at p4.

If you are unable to use the template, please email guidelines@blood.gov.au.

**Draft Research Protocol for the review of the evidence base for the update
of Patient Blood Management Guidelines: Modules 2 – 6**

For Office Use Only

Where do I send my submission?

Please email your submission to guidelines@blood.gov.au.

If you are not able to e-mail your submission you can mail or fax a hard copy to:

Attention: Donna Cassoni
Patient Blood Management Guideline Development
National Blood Authority
Locked Bag 8430
CANBERRA ACT 2601

Fax: (02) 6151 5300

The closing date for submissions is **5pm on Friday 9 November 2018**.

What will happen to my submission?

All submissions will be collated by the National Blood Authority and considered by the JBC Working Group.

The NBA may include your name, or the name of your organisation with your submission, and/or quotes from your submission in any reports prepared relating to the Research Protocol.

--

Cover Sheet

Please ensure that all details on this page are completed.

College/Society					
Organisation name	AUSTRALASIAN COLLEGE FOR EMERGENCY MEDICINE				
Postal Address of Organisation	34 JEFFCOTT STREET				
Suburb	WEST MELBOURNE	State	VIC	Postcode	3003

College/Society representative			
Name	BISWADEV MITRA		
Position	FELLOW		
Phone	03 9076 2782	Fax	03 9076 2699
Email	Biswadev.mitra@monash.edu		
Signature			

College/Society official who has authorised submission			
Name	Helena Maher		
Position	Manager, Policy and Advocacy		
Phone	0393200423	Fax	
Email	helena.maher@acem.org.au		
Signature			

** Personal information on this form is collected to enable the NBA to clarify or seek further information on submissions, if required.*



Submission Template

Please type directly into the tables below. Add extra rows as needed.

It is not necessary to comment on all the research questions, only those for which you have views.

Please provide a rationale for any proposed amendments.

1. ACTIVE RESEARCH QUESTIONS AND PICO CRITERIA (pages 12 to 31)

An *example* of feedback on a Research Questions and PICO Criteria can be found below:

Question #	Page Number	Question:	Attached documentation Y/N
U1-Q13	18	In surgical patients, what is the effect of perioperative iron therapy to increase haemoglobin concentration on patient outcomes and RBC transfusion?	
Comments			
<i>Include your proposed amendments and rationale here</i>			

Question #	Page Number	Question:	Attached documentation Y/N
2(U1-GQ02)	14	In (all adult) patients, what is the effect of red blood cell (RBC) transfusion on patient outcomes? (Interventional Question)	N
Comments			
<p>Would you consider the population (all adult patients) to be separated into clinically important subgroups who may have different outcomes. For example:</p> <ul style="list-style-type: none"> - Patient with palliative management - Oncology patients - Haematological malignancies <p>Additionally, it may be useful to pre-specify the outcomes being considered, i.e. quality of life rather than mortality alone</p>			

Question #	Page Number	Question:	Attached documentation Y/N

Draft Research Protocol for the review of the evidence base for the update of Patient Blood Management Guidelines: Modules 2 – 6

For Office Use Only

--

14 (U1-Q14)	19	In patients undergoing invasive procedures, what effect does the cessation and timing of cessation of medications that affect haemostasis, have on patient outcomes and red blood cell (RBC) or blood component transfusion? <i>(Interventional Question)</i>	N
Comments			
We recommend consideration be given to over-the-counter medications as well, e.g. fish-oils (https://www.tga.gov.au/publication-issue/medicines-safety-update-no2-2010) and NSAIDs.			

Question #	Page Number	Question:	Attached documentation Y/N
22 (U1-Q22)	27	In maternity patients, what is the effect of non-obstetric strategies that aim to minimise maternal blood loss in the peripartum period on patient outcomes and red blood cell (RBC) or blood component transfusion? <i>(Interventional Question)</i>	N
Comments			
Please consider examining and adding the Role of desmopressin in PPH (Ekelund K, Hanke G, Stensballe J, Wikkelsøe A, Albrechtsen CK, Afshari A. Hemostatic resuscitation in postpartum haemorrhage – a supplement to surgery. Acta Obstet Gynecol Scand 2015; 94: 680- 692)			

Question #	Page Number	Question:	Attached documentation Y/N
25 (U1-Q25)	30	In neonates/paediatric patients, what is the effect of strategies that minimise blood loss and/or reduce the need for red blood cell (RBC) transfusion on patient outcomes? <i>(Interventional Question)</i>	N
Comments			
Please consider guidelines on the role of vasopressor agents in acute life threatening haemorrhage (as per European bleeding guidelines)			

